. Author manuscript; available in PMC: 2014 Dec 1.

Published in final edited form as: Ann Surg Oncol. 2013 Sep 18;20(0 3):S725–S730. doi: 10.1245/s10434-013-3262-5

TABLE 1.

Patient demographic and pathologic characteristics at vaccine 1, day 0

Characteristic	TLC <1,500 cells/mm³ (n = 10)	TLC ≥ 1,500 cells/mm³ (n = 49)	p^a
Age at surgery (year), median (range)	67 (52–83)	62 (40–82)	0.137
Male, n (%)	8 (80 %)	28 (57 %)	0.288
Lymph node positive, n (%)	9 (90 %)	43 (88 %)	> 0.99
Margin positive, n (%)	5 (50 %)	12 (24 %)	0.133
Tumor size, cm, median (range)	2.90 (1.50–4.50)	3.00 (1.30–6.00)	0.800
Histologic grade > 2, n (%)	1 (10 %)	21(43 %)	0.074
Vaccine 2, day 0, TLC of < 500 cells/mm³, n (%)^b	2 (40 %)	5 (17 %)	0.256

TLC total lymphocyte count

p values are based on Wilcoxon rank sum and Fisher’s exact test for continuous and categorical variables, respectively

Percentage calculated from the 35 participants who proceeded to vaccine 2